189 related articles for article (PubMed ID: 8648761)
1. Monkeys immunized with intertypic chimeric dengue viruses are protected against wild-type virus challenge.
Bray M; Men R; Lai CJ
J Virol; 1996 Jun; 70(6):4162-6. PubMed ID: 8648761
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of molecular strategies to develop a live dengue vaccine.
Lai CJ; Bray M; Men R; Cahour A; Chen W; Kawano H; Tadano M; Hiramatsu K; Tokimatsu I; Pletnev A; Arakai S; Shameem G; Rinaudo M
Clin Diagn Virol; 1998 Jul; 10(2-3):173-9. PubMed ID: 9741643
[TBL] [Abstract][Full Text] [Related]
3. Immunization of rhesus monkeys with a recombinant of modified vaccinia virus Ankara expressing a truncated envelope glycoprotein of dengue type 2 virus induced resistance to dengue type 2 virus challenge.
Men R; Wyatt L; Tokimatsu I; Arakaki S; Shameem G; Elkins R; Chanock R; Moss B; Lai CJ
Vaccine; 2000 Jul; 18(27):3113-22. PubMed ID: 10856791
[TBL] [Abstract][Full Text] [Related]
4. Tick-borne Langat/mosquito-borne dengue flavivirus chimera, a candidate live attenuated vaccine for protection against disease caused by members of the tick-borne encephalitis virus complex: evaluation in rhesus monkeys and in mosquitoes.
Pletnev AG; Bray M; Hanley KA; Speicher J; Elkins R
J Virol; 2001 Sep; 75(17):8259-67. PubMed ID: 11483771
[TBL] [Abstract][Full Text] [Related]
5. Construction of intertypic chimeric dengue viruses exhibiting type 3 antigenicity and neurovirulence for mice.
Chen W; Kawano H; Men R; Clark D; Lai CJ
J Virol; 1995 Aug; 69(8):5186-90. PubMed ID: 7609092
[TBL] [Abstract][Full Text] [Related]
6. Chimeric dengue type 2/type 1 viruses induce immune responses in cynomolgus monkeys.
Butrapet S; Rabablert J; Angsubhakorn S; Wiriyarat W; Huang C; Kinney R; Punyim S; Bhamarapravati N
Southeast Asian J Trop Med Public Health; 2002 Sep; 33(3):589-99. PubMed ID: 12693596
[TBL] [Abstract][Full Text] [Related]
7. Vaccine candidates for dengue virus type 1 (DEN1) generated by replacement of the structural genes of rDEN4 and rDEN4Delta30 with those of DEN1.
Blaney JE; Sathe NS; Hanson CT; Firestone CY; Murphy BR; Whitehead SS
Virol J; 2007 Feb; 4():23. PubMed ID: 17328799
[TBL] [Abstract][Full Text] [Related]
8. Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys.
Blaney JE; Matro JM; Murphy BR; Whitehead SS
J Virol; 2005 May; 79(9):5516-28. PubMed ID: 15827166
[TBL] [Abstract][Full Text] [Related]
9. Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine.
Guirakhoo F; Arroyo J; Pugachev KV; Miller C; Zhang ZX; Weltzin R; Georgakopoulos K; Catalan J; Ocran S; Soike K; Ratterree M; Monath TP
J Virol; 2001 Aug; 75(16):7290-304. PubMed ID: 11462001
[TBL] [Abstract][Full Text] [Related]
10. Preclinical development of a dengue tetravalent recombinant subunit vaccine: Immunogenicity and protective efficacy in nonhuman primates.
Govindarajan D; Meschino S; Guan L; Clements DE; ter Meulen JH; Casimiro DR; Coller BA; Bett AJ
Vaccine; 2015 Aug; 33(33):4105-16. PubMed ID: 26144900
[TBL] [Abstract][Full Text] [Related]
11. Non-structural proteins of dengue 2 virus offer limited protection to interferon-deficient mice after dengue 2 virus challenge.
Calvert AE; Huang CY; Kinney RM; Roehrig JT
J Gen Virol; 2006 Feb; 87(Pt 2):339-346. PubMed ID: 16432020
[TBL] [Abstract][Full Text] [Related]
12. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates.
Guirakhoo F; Weltzin R; Chambers TJ; Zhang ZX; Soike K; Ratterree M; Arroyo J; Georgakopoulos K; Catalan J; Monath TP
J Virol; 2000 Jun; 74(12):5477-85. PubMed ID: 10823852
[TBL] [Abstract][Full Text] [Related]
13. Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates.
Guirakhoo F; Pugachev K; Arroyo J; Miller C; Zhang ZX; Weltzin R; Georgakopoulos K; Catalan J; Ocran S; Draper K; Monath TP
Virology; 2002 Jun; 298(1):146-59. PubMed ID: 12093182
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of St. Louis encephalitis virus/dengue virus type 4 antigenic chimeric viruses in mice and rhesus monkeys.
Blaney JE; Speicher J; Hanson CT; Sathe NS; Whitehead SS; Murphy BR; Pletnev AG
Vaccine; 2008 Aug; 26(33):4150-9. PubMed ID: 18586359
[TBL] [Abstract][Full Text] [Related]
15. Immunization of monkeys with baculovirus-dengue type-4 recombinants containing envelope and nonstructural proteins: evidence of priming and partial protection.
Eckels KH; Dubois DR; Summers PL; Schlesinger JJ; Shelly M; Cohen S; Zhang YM; Lai CJ; Kurane I; Rothman A
Am J Trop Med Hyg; 1994 Apr; 50(4):472-8. PubMed ID: 8166355
[TBL] [Abstract][Full Text] [Related]
16. Molecularly engineered live-attenuated chimeric West Nile/dengue virus vaccines protect rhesus monkeys from West Nile virus.
Pletnev AG; Claire MS; Elkins R; Speicher J; Murphy BR; Chanock RM
Virology; 2003 Sep; 314(1):190-5. PubMed ID: 14517072
[TBL] [Abstract][Full Text] [Related]
17. Chimeric West Nile/dengue virus vaccine candidate: preclinical evaluation in mice, geese and monkeys for safety and immunogenicity.
Pletnev AG; Swayne DE; Speicher J; Rumyantsev AA; Murphy BR
Vaccine; 2006 Sep; 24(40-41):6392-404. PubMed ID: 16831498
[TBL] [Abstract][Full Text] [Related]
18. Substitution of the structural genes of dengue virus type 4 with those of type 2 results in chimeric vaccine candidates which are attenuated for mosquitoes, mice, and rhesus monkeys.
Whitehead SS; Hanley KA; Blaney JE; Gilmore LE; Elkins WR; Murphy BR
Vaccine; 2003 Oct; 21(27-30):4307-16. PubMed ID: 14505913
[TBL] [Abstract][Full Text] [Related]
19. A live, attenuated dengue virus type 1 vaccine candidate with a 30-nucleotide deletion in the 3' untranslated region is highly attenuated and immunogenic in monkeys.
Whitehead SS; Falgout B; Hanley KA; Blaney JE; Markoff L; Murphy BR
J Virol; 2003 Jan; 77(2):1653-7. PubMed ID: 12502885
[TBL] [Abstract][Full Text] [Related]
20. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.
Guirakhoo F; Kitchener S; Morrison D; Forrat R; McCarthy K; Nichols R; Yoksan S; Duan X; Ermak TH; Kanesa-Thasan N; Bedford P; Lang J; Quentin-Millet MJ; Monath TP
Hum Vaccin; 2006; 2(2):60-7. PubMed ID: 17012873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
